The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH AL 2020 | MBG453 with hypomethylating agents in AML and high-risk MDS
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, details the results of the Phase Ib multicenter, open-label study of the anti-TIM-3 antibody sabatolimab in combination with hypomethylating agents in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
